The predictors of response to antidepressant treatment in patients with resistant depression-an integrative approach

Not Applicable

Completed

• Conditions: More than one previous unsuccessful antidepressant trial lasting 4 or more weeks in the current episode of depression; Mental and Behavioural Disorders; Depressive episode, unspecified

• Registration Number: ISRCTN25983493
• Lead Sponsor: Ministry of Health (Czech Republic) - Internal Grant Agency

Brief Summary

1. 2017 results in https://www.ncbi.nlm.nih.gov/pubmed/27660994 (added 22/01/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-06-27
• Study Completion: 2015-12-31
• Last Update Posted: 11 February 2019

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Patients suffering from Major depressive disorder (recurrent or single episode) diagnosed according to Diagnostic and Statistical Manual of the American Psychiatric Association-IV. revision (DSM-IV) criteria, confirmed using The Mini-International Neuropsychiatric Interview - M.I.N.I., Czech version 5.0.0.
2. Patients fulfilling at least Stage I (=1 previous, unsuccessful, adequate, antidepressant treatment) criteria for resistant depression according to Thase and Rush.
3. The mental ability to understand and sign Informed Consent Form.
4. The score in the Montgomery and Åsberg Rating Scale (MADRS) =25 and the score in Clinical Global Impression (CGI)=4.
5. Inpatients.
6. Age between 18 and 65 years, either sex

Exclusion Criteria

1. Contraindications of treatment with selective serotonin reuptake inhibitors (SSRIs) (citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine) according to Summary of Product (SPC)
2. Psychiatric comorbidity on axis I and II according to DSM IV in the 6 months before enrollment to the study
3. Patients with severe somatic disorders (cardiovascular disease, neoplasms, endocrinology disorders etc.) that could be associated with depression due to somatic disease.
4. Patients treated with electroconvulsive therapy less than 3 month before enrollment or suffering from neurologic disorder (e.g., epilepsy, head trauma with loss of consciousness) and patients using any treatment which can strongly affect EEG.
5. Patients who were treated unsuccessfully with more than one SSRIs during index episode.

Study & Design

• Study Type: Interventional
• Study Design: Not specified